Biochemistry, Genetics and Molecular Biology (all)
Abstract :
[en] Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-024-03261-7, published online 13 September 2024. In the version of this article initially published, members of the DESTINY-Breast12 study group were not included by the journal in the full text. In Table 1, under the “Prior CNS therapies n (%)” section, seven rows have been added, in addition to the original CNS radiotherapy, WBRT and SRS rows. In Table 1 and in the Results: Patients section, “intracranial therapy” has been amended to “CNS radiotherapy,” while the text “the type of intracranial radiotherapy was not always recorded by investigators, and only WBRT and SRS intracranial radiotherapy were reported” has been removed. All changes appear in the HTML and PDF versions of the article.
Disciplines :
Oncology
Author, co-author :
Harbeck, Nadia ; Breast Center, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Munich, LMU University Hospital, Munich, Germany. nadia.harbeck@med.uni-muenchen.de
Ciruelos, Eva ; Hospital Universitario 12 de Octubre, Madrid, Spain
Jerusalem, Guy ; Université de Liège - ULiège > Département des sciences cliniques > Oncologie
Müller, Volkmar; University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Niikura, Naoki; Tokai University School of Medicine, Kanagawa, Japan
Viale, Giuseppe; Department of Pathology and Laboratory Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy
Bartsch, Rupert; Division of Oncology, Department of Medicine 1, Medical University of Vienna, Vienna, Austria
Kurzeder, Christian; Breast Center, University Hospital Basel, Basel, Switzerland
Higgins, Michaela J; St. Vincent's University Hospital, UCD Cancer Trials Cluster, Dublin, Ireland
Connolly, Roisin M ; Cancer Research @UCC, College of Medicine and Health, University College Cork, Cork, Ireland ; Cancer Trials Cork, CUH/UCC Cancer Center, Cork University Hospital, Cork, Ireland
Baron-Hay, Sally ; Department of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW, Australia
Gión, María; IOB-Madrid, Beata María Ana Hospital, Madrid, Spain ; Department of Medical Oncology, Ramón y Cajal University Hospital, Madrid, Spain
Guarneri, Valentina; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy ; Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy
Bianchini, Giampaolo ; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy ; School of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy
Wildiers, Hans ; Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
Escrivá-de-Romaní, Santiago; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain
Prahladan, Manoj; Global Medical Affairs, Oncology R&D, AstraZeneca, Cambridge, UK
Bridge, Helen; Oncology Global Medical Affairs / Payer Biometrics, AstraZeneca, Macclesfield, UK
Kuptsova-Clarkson, Nataliya; Patient Safety, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA
Scotto, Nana; Oncology Global Medical Affairs, AstraZeneca, Baar, Switzerland
Verma, Sunil; Oncology Franchise, AstraZeneca, Gaithersburg, MD, USA
Lin, Nancy U ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.
Alternative titles :
[en] Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial(Nature Medicine, 10.1038/s41591-024-03261-7)
Publication date :
2024
Journal title :
Nature Medicine
ISSN :
1078-8956
eISSN :
1546-170X
Publisher :
Springer Science and Business Media LLC, United States
